The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice

Julia Day, Anna Antony, William Tillett, Laura C Coates

Research output: Contribution to journalReview articlepeer-review

10 Downloads (Pure)

Abstract

Psoriatic arthritis is a heterogeneous condition with substantial challenges in optimising outcome measures for both clinical trials and daily practice. As with other inflammatory arthritides, there is no gold standard instrument for measuring disease activity or impact, both of which are key to evaluate therapeutic approaches in trials and monitor disease in daily practice. A wide range of domains have been highlighted in the Outcome Measures in Rheumatology (OMERACT) core domain set for psoriatic arthritis; reflecting the disease involvement in multiple tissues (joints, tendons, skin, and spine) and the heterogenous impact of the disease on individuals. This Review summarises the current evidence around outcome measure selection, considering factors such as unidimensional versus multidimensional outcomes, continuous versus binary measures, and the feasibility of these approaches in trials compared with clinical practice.

Original languageEnglish
Pages (from-to)e220-e228
Number of pages9
JournalThe Lancet Rheumatology
Volume4
Issue number3
Early online date20 Jan 2022
DOIs
Publication statusPublished - 31 Mar 2022

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice'. Together they form a unique fingerprint.

Cite this